NanaBis (NanoCelle CBD/THC)

CLINICAL TRIAL

An observational study investigating and auditing the safety, tolerability and further efficacy characteristics of a pharmaceutical grade cannabis medicine (NanaBis™) prescribed to eligible patients for the management of cancer related and non-cancer related pain in general and specialty medical practices.

FORMULATION

NanaBisTM is an investigative new product containing 1:1 ratio of Cannabidiol (CBD) and delta-9-trethydrocannabinol (THC), in a sub-micron spray applied to the oro-buccal membrane.

DATE of HREC approval

17 June 2019

HREC

National Institute of Integrative Medicine (NIIM) EC00436

HREC Approval ID

H0052E_2019

CTN

TBA

ANZCTR

ACTRN12619000513112

STUDY SITE

Australian general and specialty medical practices.

STATUS

Recruiting Open